title: Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer.
abstract: This phase II trial studied the antitumor effect and toxicity of weekly irinotecan (CPT-11, 125 mg/m(2) 60 min iv infusion, weekly for 4 wk plus 2 wk rest) as second-line chemotherapy in patients with advanced colorectal cancer (CRC) resistant or refractory to prior 5-fluorouracil (5-FU) therapy. Sixty-nine patients with adenocarcinoma (57% in the colon and 43% in the rectum) were enrolled. The median number of treatment cycles received per patient was 4 (range, 1-6). Overall response rate was 18% (95% CI, 9-26), with 4 complete responses (6%) and 8 partial responses (12%), and a median duration of response of 8.1 mo (95% CI, 4.2-12.1). Stable disease was observed in 19 patients (28%). The median time to disease progression was 5.2 mo (95% CI, 4.3-6.1), and the median overall survival was 13.3 mo (95% CI, 9.8-16.8 months). The toxicity profile was favorable: grade 3/4 delayed diarrhea was observed in 10 patients (14.5%) in one cycle each, and grade 3/4 neutropenia in 6 patients (8.7%) and 6 cycles (3.3%). No febrile neutropenia or infection was documented. Grade 3/4 nausea and vomiting were reported in 1 (1.4%) and 7 patients (10.1%), respectively. In conclusion, this phase II trial showed a response rate and a toxicity profile of weekly CPT-11 in line with the results of prior phase II studies.
authors.affiliation: Hospital general de Guadalajara, Spain. javiercasinello@terra.es
authors.forename: J
authors.initials: J
authors.lastname: Cassinello
authors.forename: P
authors.initials: P
authors.lastname: López-Alvarez
authors.forename: A
authors.initials: A
authors.lastname: Martínez-Guisado
authors.forename: M
authors.initials: M
authors.lastname: Valladares
authors.forename: G
authors.initials: G
authors.lastname: Huidobro
authors.forename: R
authors.initials: R
authors.lastname: López
authors.forename: U
authors.initials: U
authors.lastname: Bohn
authors.forename: I
authors.initials: I
authors.lastname: Sevilla
authors.forename: P
authors.initials: P
authors.lastname: Ballesteros
authors.forename: M
authors.initials: M
authors.lastname: Jorge
authors.forename: R
authors.initials: R
authors.lastname: Pérez-Carrión
authors.forename: J L
authors.initials: JL
authors.lastname: Fernández
authors.forename: J
authors.initials: J
authors.lastname: Dorta
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D000328:Adult; D000368:Aged; D002166:Camptothecin / Q000008:administration & dosage* / Q000009:adverse effects* / Q000031:analogs & derivatives*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D018450:Disease Progression; D004334:Drug Administration Schedule; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000077146:Irinotecan; D002166:Camptothecin